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Abstract
Background: Since prion gene-knockout mice do not contract prion diseases and animals in which
production of prion protein (PrP) is reduced by half are resistant to the disease, we hypothesized
that bovine animals with reduced PrP would be tolerant to BSE. Hence, attempts were made to
produce bovine PRNP (bPRNP) that could be knocked down by RNA interference (RNAi)
technology. Before an in vivo study, optimal conditions for knocking down bPRNP were determined
in cultured mammalian cell systems. Factors examined included siRNA (short interfering RNA)
expression plasmid vectors, target sites of PRNP, and lengths of siRNAs.
Results: Four siRNA expression plasmid vectors were used: three harboring different cloning sites
were driven by the human U6 promoter (hU6), and one by the human tRNAVal promoter. Six target
sites of bovine PRNP were designed using an algorithm. From 1 (22 mer) to 9 (19, 20, 21, 22, 23,
24, 25, 27, and 29 mer) siRNA expression vectors were constructed for each target site. As targets
of siRNA, the entire bPRNP coding sequence was connected to the reporter gene of the fluorescent
EGFP, or of firefly luciferase or Renilla luciferase. Target plasmid DNA was co-transfected with
siRNA expression vector DNA into HeLaS3 cells, and fluorescence or luminescence was
measured. The activities of siRNAs varied widely depending on the target sites, length of the
siRNAs, and vectors used. Longer siRNAs were less effective, and 19 mer or 21 mer was generally
optimal. Although 21 mer GGGGAGAACTTCACCGAAACT expressed by a hU6-driven plasmid
with a Bsp MI cloning site was best under the present experimental conditions, the corresponding
tRNA promoter-driven plasmid was almost equally useful. The effectiveness of this siRNA was
confirmed by immunostaining and Western blotting.
Conclusion: Four siRNA expression plasmid vectors, six target sites of bPRNP, and various lengths
of siRNAs from 19 mer to 29 mer were examined to establish optimal conditions for knocking
down of bPRNP  in vitro. The most effective siRNA so far tested was 21 mer
GGGGAGAACTTCACCGAAACT driven either by a hU6 or tRNA promoter, a finding that
provides a basis for further studies in vivo.
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Background
Prion diseases are characterized by a prolonged latent
period and a distinctive neuropathology that includes
spongiform change, gliosis, neuronal loss, and the accu-
mulation of an abnormal prion protein (PrPSc), an isomer
of the normal cellular prion protein (PrPC) encoded by
the prion gene (PRNP), in affected brains. PrPC, a glyco-
protein, is anchored to the outer surface of neurons and to
a lesser extent of lymphocytes and other cells. The func-
tion of PrPC is not known, but seems to be physiologically
important because PRNP has been found in all animals
examined (cattle, goats, hamsters, humans, mice, rats,
sheep) as well as in the chicken. The conversion of PrPC to
PrPSc is believed to occur not as a result of viral or bacterial
infection but as a result of interaction with exogenously
introduced, self-replicating PrPSc or by a very rare sponta-
neous event according to the protein-only hypothesis [1].
Although data have been accumulated using BSE-infected
mice [2] and Prnp knockout mice as well [3-5], the physi-
ological role of PrPC still remains to be clarified. From the
pathological viewpoint, however, it is important that mice
devoid of PrPC are resistant to scrapie and fail to propagate
prions [6-9] and that the introduction of PrP-encoding
transgenes restores susceptibility to the disease [10].
Prnp0/+ mice, which have about half the normal level of
PrPC in their brains, show enhanced resistance to scrapie,
as revealed by a significant delay in the onset and progres-
sion of clinical disease, while in wild-type animals, an
increase in prion titer and PrPSc levels was followed within
weeks by symptoms of scrapie and death [11]. These find-
ings suggest that the production of BSE-resistant cattle
would be possible by knocking down bovine PRNP
(bPRNP) using RNA interference (RNAi) technology.
The injection of double-stranded RNA (dsRNA) into the
cells of worms led to efficient sequence-specific gene
silencing, referred to as RNAi [12]. This phenomenon also
occurs in fly and plant cells, but not in mammalian cells.
However, Elbashir et al. [13] demonstrated that 21~22-nt
dsRNA with 2-nt 3' overhangs (short interfering RNA:
siRNA) can induce sequence-specific gene silencing with-
out non-specific inhibition of gene expression in cultured
mammalian cells. siRNA expression systems using plas-
mid vectors are advantageous, because their use makes it
possible to make transgenic animals, and the incorpora-
tion of one or a few plasmids into the nucleus would pro-
vide enough siRNA to induce RNAi. Soon after the
discovery by Elbashir et al. [13] of the occurrence of RNAi
in mammals, siRNA expression vector systems were devel-
oped [14-16]. The current understanding of the mecha-
nisms of RNAi is as follows: dsRNA is digested to siRNA
by the actions of Dicer, a family member of RNase III
enzymes [17], and one strand of the siRNA unwound with
the aid of ATP hydrolysis is incorporated into RISC (RNA-
induced silencing complex) which has RNase activity
[18]. mRNA with the sequence complementary to the
siRNA is cleaved by RISC, knocking-down the gene
expression of a specified mRNA (Dykxhoom et al., review
[19]). Here we present optimal conditions, including
siRNA expression promoters, target sites, and lengths of
siRNAs, for knocking down bPRNP.
Results
Target plasmids with the insertion of a stop codon 
between reporter and target genes
In previous experiments, a full-length mouse Prnp gene
with ATG (762 bp) or without ATG (759 bp) and three
other fragments (645, 486, and 306 bp from the stop
codon) were ligated in-frame into pDsRed2-C1. Cells
transfected with the full-length construct and the plasmid
with the 486-bp fragment did not show fluorescence, but
cells transfected with the plasmids containing the 645-bp
and 306-bp fragments emitted fluorescence, indicating
that in-frame inserts might stop the production of the flu-
orescent reporter depending on the sequence. When the
full-length bPRNP  was inserted into pEGFP-C1 down-
stream from the EGFP stop codon, cells transfected with
the construct emitted fluorescence. Therefore, a stop
codon was inserted between the reporter and bPRNP in all
the target plasmids, all of which were found to be effective
in producing fluorescence in transfected cells (Table 1).
Dose-response relationship between fluorescence and 
plasmid DNA
When the dose-response relationship was examined using
pEGFP-bPrP, linearity of EGFP fluorescence was obtained
below 500 ng/well; a total of 400 ng/well or less was
therefore used in subsequent experiments.
Comparison of sensitivity of fluorescence versus 
luminescence and lengths of siRNAs
When the sensitivity of the fluorescent reporter of pEGFP-
bPrP (Fig. 1A) and the luminescent reporter of pGL3-bPrP
(Fig. 1B) was compared, detection of the EGFP fluores-
cence was found to be less sensitive than detection of the
luminescence produced by firefly luciferase. This may be
due to the comparatively long life of EGFP protein. Fig. 1A
also shows that shorter siRNAs (around 23 mer) were
more effective in silensing bPRNP expression than longer
ones (27 and 29 mer), and that piGENE tRNA was more
effective than piGENE CACC-S/K. Fig. 1B compares a nar-
row range of lengths of siRNAs expressed by three plasmid
vectors. On the whole, 21 or 22 mer was the most effective
silencer, and the differences between them were minor.
Vectors harboring internal control emitters
To determine the effectiveness of siRNAs, measurements
of reporter protein levels were made using fluorescence or
luminescence reporter assays (Fig. 1A and 1B). Three vec-BMC Biotechnology 2007, 7:44 http://www.biomedcentral.com/1472-6750/7/44
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tors in which an internal control was integrated into a sin-
gle target vector, pFluc-bPrP-Rluc, pFluc-Rluc-bPrP, and
pTKFluc-bPrP-Rluc, were constructed (Table 1). Since the
results obtained with pTKFluc-bPrP-Rluc were almost the
same as those for pFluc-Rluc-bPrP and pTKFluc-bPrP-
Rluc, the results for pFluc-bPrP-Rluc are shown in Fig. 1C,
in which effective target sites are compared (see next sec-
tion).  Renilla luminescence was always much stronger
than firefly luminescence driven by either the SV40 or
HCV-TK promoter. Although the sensitivity of siRNA
effects detected using these double emitter vectors was
low compared with that of a single emitter such as pGL3-
bPrP, the relative effectiveness of siRNA was reproducible.
Therefore, these vectors appeared to be useful for assaying
the relative activity.
Effective target sites
Six siRNA target sites were predicted in the bPRNP
sequence by using an algorithm [20] (Nos. 1, 3, 5, 6, 15
and 17, Table 2). Six different 22-nt targets (Nos. 2, 4, 5,
8, 16 and 18, Table 2), except for No. 8, where a 21 mer
was used, were compared using a single expression vector,
piGENE hU6 (Fig. 1C). The target vector was pFluc-bPrP-
Rluc and the sensitivity was quite low, as described previ-
ously, but relative activities could be determined. No. 8
with the sequence 5'-GGGGAGAACTTCACCGAAACT-3'
was the best silencer. Fig. 1D shows differences in siRNA
activities examined using combinations of four target sites
of 22 nt (Nos. 2, 4, 9, and 16, Table 2) and three expres-
sion vectors (piGENE CACC-S/K, piGENE S/K, and
piGENE tRNA. Table 3). As for vectors, piGENE S/K was
the best, followed by piGENE tRNA; and piGENE CACC-
S/K was almost always the worst. As for target sites,
sequence No. 9, the 22 mer version of No. 8 (21 mer), was
the best and No. 4 was the worst using all three vectors.
Differences between 21 mer and 22 mer were minimal in
the three vectors (Fig. 1D).
Comparison of siRNA expression vectors
The structure of the cloning sites of the siRNA expression
vectors is shown in Table 3. Fig 1E compares the effective-
ness of the siRNA expression vectors. Fig. 1E shows a typ-
ical result, and the order of effectiveness was almost
always piGENE hU6, piGENE S/K, piGENE tRNA, and
piGENE CACC-S/K. The difference between piGENE hU6
and piGENE S/K was minimal and sometimes the order of
these two was reversed.
bPRNP silencing as revealed by immunostaining
Full-length PrPC and truncated PrPC as targets and three
antibodies, SAF32, P6488, and anti-FLAG, recognizing
different regions, the upstream, mid-part, and C-terminal
tag, respectively, were used for immunostaining experi-
ments. Full-length PrPC could be detected equally using
the three antibodies; the fluorescence signal intensities,
which were moderate, were almost the same (Fig. 2A and
2C) among the three. The number of fluorescent cells
depended on the amount of target DNA applied. When
800 ng/well was applied, approximately 50% of cells were
fluorescence-positive, and when 200 ng/well was used,
20–30% were positive. When target DNA was co-trans-
fected with siRNA expression vector DNA, almost no flu-
orescence was detected (Fig. 2B). This was true for both
hU6 and tRNA promoter-driven vectors (Fig. 2B and 2D).
Truncated PrPC could be detected using P6488 (Fig. 2E)
and anti-FLAG antibody. As expected, SAF32 could not
detect truncated PrPC, which lacks the N-terminal region
(not shown). The intensity of fluorescence was much
stronger than that of full-length PrPC (compare Fig. 2E
with A and C). Perinuclear regions were strongly stained
(Fig. 2E). The fluorescence almost disappeared when tar-
get DNA was co-transfected with siRNA expression plas-
mid DNA derived from either piGENE hU6 (Fig. 2F) or
piGENE tRNA, indicating the effectiveness of siRNA.
bPRNP silencing as revealed by Western blotting
When a full-length PrPC was transiently expressed and
detected using the antibody SAF32, 25- to 30-kDa bands
were detected, with the 26-kDa band being most intense.
When target DNA was co-transfected with siRNA expres-
sion vector DNA, almost no bands were detected (Fig 3),
indicating the effectiveness of siRNA. This was true for
both hU6 (Fig 3, lanes 8–10) and tRNA (Fig 3, lanes14–
16) promoter-driven vectors. The bands in lanes 5–7 were
darker than those in lanes 11–13. Sonication of the sam-
ples in lanes 11–13 seemed to have been insufficient,
because intense bands were seen at the sites of sample
application. The major band was 26 kDa, non-glyco-
Table 1: Characteristics of target vectors
Vector Promoter 1 Reporter 1 Target Promoter 2 Reporter 2 Target
pEGFP-bPrP CMV EGFP bPRNP
pGL3-bPrP SV40 Fire-fly luciferase bPRNP
pFluc-bPrP-Rluc SV40 Fire-fly luciferase bPRNP HSV-TK Renilla luciferase*
pFluc-Rluc-bPrP SV40 Fire-fly luciferase* HSV-TK Renilla luciferase bPRNP
pTKFluc-bPrP-
Rluc
HSV-TK Fire fly luciferase bPRNP HSV-TK Renilla luciferase*
*, used as the internal control.BMC Biotechnology 2007, 7:44 http://www.biomedcentral.com/1472-6750/7/44
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Effects of siRNA expression vectors on bPRNP Figure 1
Effects of siRNA expression vectors on bPRNP. A and B, effects of different lengths of siRNAs expressed by different 
vectors. A: piGENE hU6-EGFP was a positive control siRNA vector for EGFP. Numerals after vectors indicate the lengths of 
siRNA; 19, 23, 25, 27, and 29 correspond to No. 6, 10, 12, 13, and 14 in Table 2, respectively. B: piGENE Fluc is a positive con-
trol siRNA vector against firefly luciferase. Numerals after vectors indicate the lengths of siRNA; 19, 20, 21, and 22 correspond 
to No. 6, 7, 8, and 9 in Table 2, respectively. C and D, effects of different target sites and expression vectors on siRNA activi-
ties. C: numerals after vectors indicate the start sites of siRNA; 132, 372, 616, and 725 correspond to No. 2, 4, 9, and 16 in 
Table 2, respectively. D: as for numerals after vectors, see the legend to C. E: comparison of vector activities. Vectors 
expressed 19 mer, and the sequence corresponds to No. 6 in Table 2.
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sylated PrPC. Glycosylated PrPC appeared at around 32
kDa, as can be clearly seen in lanes 5–7, and very faintly
seen in lanes 11–13. The nature of the strong bands at
around 40 kDa in lanes 5–7 is not known. Truncated PrPC
could not be detected using SAF32, as expected, but could
be detected using P6488 antibody (data not shown).
Discussion
The hU6 promoter has been widely used to drive siRNA
expression in plasmid vectors, but tRNA promoter-driven
vectors have rarely been used; therefore, in this study
piGENE tRNA was used for comparison with piGENE
hU6. These two vectors have different cloning sites, i.e.,
piGENE hU6 has a Bsp MI cloning site, while the piGENE
tRNA has a Sac I, Bgl II, Not I, Kpn I, and Eco RV cloning
site, (Table 3). The instructions of the manufacturer are
also different: 19 to 22 mer is reccomended for piGENE
hU6 and less than or close to 30 mer for piGENE tRNA.
siRNA activities are affected by the promoters, siRNA
lengths, and cloning site structures. To compare the effec-
tiveness of piGENE hU6 and piGENE tRNA, two other
siRNA-expression vectors were constructed; these were
piGENE CACC-S/K and piGENE S/K, which had a com-
mon cloning site consisting of Sac I, Bgl II, Eco RV, and Kpn
I recognition sequences. Using the Sac I and Kpn I sites was
convenient because the same constructs could be
employed as cassettes for piGENE CACC-S/K, piGENE S/
K, and piGENE tRNA (Table 3). CACC was introduced
into piGENE CACC-S/K because the natural human U6
promoter habors a G just after CACC, which enhances
transcription [20].
siRNA activities can depend on the target genes and their
sequences, and therefore definite and universal conclu-
sions cannot be made. However, the present data indicate
that a shorter siRNA (around 19 to 22 mer rather than 30
mer) is better for piGENE tRNA. As a whole, piGENE hU6
showed higher levels of siRNA expression activity than
piGENE tRNA. piGENE hU6 and piGENE S/K had almost
the same levels of activity, but the former seemed to be
slightly better. The Sac I recognition site is GAGCTC and
the insertion of DNA for siRNA expression occurred just
after this site. On the other hand, the inserts come after
CACCGAGCTC in piGENE CACC-S/K, the siRNA tran-
scription of which might start from G, A, or G in the Sac I
recognition site, and Dicer counts base numbers from
these starting sites. An unexpected early start to transcrip-
tion would leave several bases at the 3' end behind and
lead to a shortage of matching bases to target mRNAs, less-
ening siRNA acrtivity.
As for the length of siRNA, 22 mer was generally the best
(Fig. 1B), although 21 mer sometimes showed similar or
better activity. However, 20 mer usually showed less activ-
Table 2: Target sequences examined
No. Positiona sequence nt Constructed vectors (❍)b Valuec
hU6 CACC-S/K S/K tRNA
1 132–150 GGGCAGTCCTGGAGGCAAC 19 ❍❍ ❍ ❍ 0.779
2 132–153 GGGCAGTCCTGGAGGCAACCGT 22 ❍❍ ❍ ❍
3 372–390 AGGAGCTGCTGCAGCTGGA 19 ❍❍ ❍ ❍ 0.775
4 372–393 AGGAGCTGCTGCAGCTGGAGCA 22 ❍❍ ❍ ❍
5 569–591 GTGTCAATATCACAGTCAAGGA 22 ❍ 0.757
6 616–634 GGGGAGAACTTCACCGAAA 19 ❍❍ ❍ ❍ 0.852
7 616–635 GGGGAGAACTTCACCGAAAC 20 ❍❍ ❍ ❍
8 616–636 GGGGAGAACTTCACCGAAACT 21 ❍❍ ❍ ❍
9 616–637 GGGGAGAACTTCACCGAAACTG 22 ❍❍ ❍ ❍
10 616–634 GGGGAGAACTTCACCGAAACTGA 23 ❍❍ ❍ ❍
11 616–634 GGGGAGAACTTCACCGAAACTGAT 24 ❍
12 616–634 GGGGAGAACTTCACCGAAACTGACA 25 ❍❍ ❍ ❍
13 616–634 GGGGAGAACTTCACCGAAACTGACATC 27 ❍❍ ❍ ❍
14 616–634 GGGGAGAACTTCACCGAAACTGACATCAA 29 ❍❍ ❍ ❍
15 725–743 GTGTGATCCTCTTCTCTTC 19 ❍❍ ❍ ❍ 0.772
16 725–746 GTGTGATCCTCTTCTCTTCCCC 22 ❍❍ ❍ ❍
17 730–748 ATCCTCTTCTCTTCCCCTC 19 ❍ 0.752
18 730–751 ATCCTCTTCTCTTCCCCTCCTG 22 ❍
a, Position 1 starts from A of ATG, the first codon of bPRNP. b, hU6, CC-S/K, S/K, and tRNA indicate piGENE hU6, piGENE CACC-S/K, piGENE S/
K, and piGENE tRNA, respectively (Table 3). Open circles designate construction of vectors. c, Values were obtained from the prediction algorithm 
[20].BMC Biotechnology 2007, 7:44 http://www.biomedcentral.com/1472-6750/7/44
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ity than 19 mer, 21 mer or 22 mer (Fig. 1B). The reasons
for this are not known, but Dicer's mechanisms of action
might be involved.
The target sequence No. 6, 5'-GGGGAGAACTTCAC-
CGAAA-3', achieved the highest score among the six tar-
gets (Table 2). Principles for the prediction of a favorable
siRNA have been proposed [21,22]. One of the key factors
in RNAi is the assembly of RISC, which mediates target
RNA cleavage. The sense and anti-sense strands of an
siRNA duplex are not equally eligible for assembly into
RISC. Both the absolute stability and relative stability of
the base pairs at the 5' end of siRNA seem to determine
which strand takes part in the RNAi pathway. Given that
in the conventional way of writing DNA sequences, the
sense strand is the upper one and the anti-sense strand is
the lower one, the left end should be tight and the right
end should be loose for the anti-sense strand to be incor-
porated into RISC. In such an analysis, No. 6 has a tight
left and a loose right end, and thus it is theoretically pre-
dicted to be effective, and was in fact found to be effective.
This tightness and looseness do not always determine the
effectiveness of RNAi, but are important factors.
The purpose of the present study was to knockdown
bPRNP  using RNAi technology. We used, however, an
siRNA expression vector driven by a hU6 promoter and
human HeLaS3 cells in an in vitro system. Is the hU6 pro-
moter active in bovine cells? Recently, we [23] cloned
chicken U6 promoters and examined their activity in
chick cells using the hU6 promoter as a comparative con-
trol. Chicken and human promoters showed almost the
same level of activity, although the activity levels were not
very high. Lambeth et al. [24] cloned a bovine U6 pro-
moter and examined its activity in MDBK (Madin Darby
Bovine Kidney) and Vero (African Green monkey kidney)
cells together with the mouse U6 promoter. The U6s of
both species gave almost identical results, suggesting that
the hU6 promoter might also be active in different mam-
malian cells. Indeed, our experiments showed that siRNA
driven by hU6 was active in bovine primary cultured cells
(data not shown).
Conclusion
To produce bPRNP-knocked down cattle using RNA inter-
ference (RNAi) technology, optimal conditions for knock-
ing down were first investigated in vitro. Four siRNA
expression plasmid vectors, six target sites of bPRNP, and
various lengths of siRNA from 19 mer to 29 mer were
examined. As a target, the bPRNP coding sequence was
connected to the reporter of the fluorescent EGFP, firefly
luciferase, or Renilla luciferase gene. When target plasmid
DNA was co-transfected with siRNA expression vector
DNA into HeLaS3 cells, and fluorescence or luminescence
was measured, siRNA of 21 mer GGGGAGAACTTCAC-
CGAAACT expressed by a hU6- or tRNA-driven plasmid
gave the best knockdown result under the present experi-
mental conditions. The effectiveness of this siRNA was
confirmed by immunostaining and Western blotting.
These data provide a basis for further studies in vivo.
Methods
Cloning of bovine prion gene PRNP
bPRNP  consists of three exons, with the open reading
frame (ORF) being located in exon 3 [25,26] (see also
GeneBank Accession No. D10612). An ORF consisting of
792 bp encoding 264 amino acid residues was amplified
by PCR with a pair of primers, one with a Bgl II site at the
terminus and the other with a Hind III site. The PCR prod-
uct was inserted into a TOPO vector (Invitrogen,
Carlsbad, CA).
PRNP target vectors
pEGFP-C1, which harbors a green fluorescent protein
gene driven by the CMV promoter, was purchased from
Becton, Dickinson and Company, Japan (Tokyo, Japan).
The multiple cloning sites of the vector were changed to
Bsr GI-Bsp EI-Spe I-Bgl II-Sal I-Afl II-Spl I-Cla I-Apa I-Sma I/
Xma I-Bam I-Xba I-Bcl I. This vector has an in-frame stop
codon, TAG, in the Spe  I recognition site (ACTAGT),
which deletes the translation of inserts cloned down-
stream of the Bgl II site so as not to interfere with the
intensity of fluorescence. pGL3 control and pRL-TK,
which harbor the firefly luciferase gene (Fluc) driven by
the SV40 promoter and the Renilla luciferase gene (Rluc)
Table 3: Structure of cloning sites of siRNA expression vectors
Vector Promoter Sequence of cloning site
piGENE hU6 hU6 CACCGTGAGCAGGTGTAAAGCCACCATGGAAGACACCTGCCAAC 
TTTTTTCAATTGGTCGACCTGCAGGCATGCAAGCTTa
piGENE CACC-S/K hU6 CACCGAGCTCAGACTCGATATCGGTACCb
piGENE S/K hU6 GAGCTCAGACTCGATATCGGTACCc
piGENE tRNA tRNA GAGCTCCAGATCTAATGCGGCCGCTTAGGTACCATAGATATCTTTTTTTCTGCAGGCATGCAAGCTTd
a: Three Bsp MI sites are underlined. b and c: Sac I, Bgl II, Eco RV, and Kpn I sites are underlined. d: Sac I, Bgl II, Not I, Kpn I, Eco RV, Pst I, and Hind III 
sites are underlined. T repeats, RNA pol III terminator signal, are italicized.BMC Biotechnology 2007, 7:44 http://www.biomedcentral.com/1472-6750/7/44
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Silencing of b PRNP by siRNA as revealed by immunostaining Figure 2
Silencing of b PRNP by siRNA as revealed by immunostaining. HeLaS3 cells were co-transfected with pbPrP- FLAG 
DNA and the control vector DNA of piGENE tRNA (A) or siRNA expression vector DNA of piGENE tRNA-616-21, the 
sequence of which is No. 8 in Table 2 (B). Cells were stained with SAF32 antibody. HeLaS3 cells were co-transfected with 
pbPrP- FLAG DNA and the control vector DNA of piGENE hU6 (C) or siRNA expression vector DNA of piGENE hU6-616-
21(D). Cells were stained with P6488 antibody. HeLaS3 cells were co-transfected with pshort-bPrP- FLAG DNA and the con-
trol vector DNA of piGENE hU6 (E) or siRNA expression vector DNA of piGENE hU6-616-21 (F). Cells were stained with 
P6488 antibody.
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driven by the HSV-TK promoter, respectively, were pur-
chased from Promega KK (Tokyo, Japan). The multiple
cloning sites and Hind III site of the pGL3 control were
removed and a new multiple cloning site, Xba I, Aat II, Bgl
II, Sal I, Pst I, Apa I, Sma I/Xma I, Spe I, Afl II, and Spl I, was
introduced just after the stop codon at the end of Fluc. The
bPRNP gene was cloned between the Bgl II and Xma I sites.
To use either Fluc or Rluc as an internal control, a combi-
nation vector, pRL-TK/SV-FL, was constructed by inserting
the Bgl II and Bam HI fragment of the pGL3 control, which
encodes the SV40 promoter and Fluc, into the Bam HI site
of pRL-TK. Three bPRNP target plasmids were constructed
from pRL-TK/SV-FL (Table 1).
PrPC-FLAG and truncated PrPC-FLAG vectors
For immunostaining and Western blot analyses, a FLAG-
tagged PrPC expression vector was constructed by intro-
ducing the full-length bPRNP  into the vector pFLAG-
Silencing of b PRNP by siRNA as revealed by Western blot analysis Figure 3
Silencing of b PRNP by siRNA as revealed by Western blot analysis. Top, protein size markers (Bio-Rad, lane 1), pro-
teins from HeLaS3 cells (lanes 2–4), proteins from cells co-transfected with pbPrP- FLAG DNA and the control vector DNA of 
piGENE hU6 (lanes 5–7) or siRNA expression vector DNA of piGENE hU6-616-21, the sequence of which is No. 8 in Table 2 
(lanes 8–10), proteins from cells co-transfected with pbPrP- FLAG DNA and the control vector DNA of piGENE tRNA (lanes 
11–13) or siRNA expression vector DNA of piGENE tRNA-616-21(lanes 14–16), and protein size markers (150, 100, 75, 35, 
25, and 15 kDa from the top, GE Healthcare). Amounts of proteins applied were 1.25 (lanes 2, 5, 8, 11, 14), 2.5 (lanes 3, 6, 9, 
12, 15), and 5.0 (lanes 4, 7, 10, 13, 16) μg/lane. The gel was stained with SAF32 antibody. Bottom, actin staining.
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CMV-5 (Sigma-Aldrich, St. Louis, MO) between the Bgl II
and Sal I sites. This vector, pbPrP- FLAG, was expected to
produce a protein consisting of PrPC (264 amino acid res-
idues) connected with FLAG (8 amino acid residues).
Since antibodies to detect PrPC might hinder the identifi-
cation of PrPC because of similarity in the molecular size,
a truncated pPrP-FLAG was also constructed by removing
the N-terminal region between Bgl II and Pvu II from PrPC-
FLAG. This pshort-bPrP- FLAG vector was expected to pro-
duce a protein consisting of the C-terminal PrPC (145
amino acid residues) connected with FLAG (8 amino acid
residues).
Selection of favorable target sites and construction of 
hairpin-type siRNA
Six target sites for siRNA were predicted using an algo-
rithm developed by Taira and Miyagishi [20]. Some deriv-
atives with lengths different from the original six sites
were constructed (Table 2). The hairpin loop sequence for
these was GTGTGCTGTCC. A few mutations in the sense
strand were introduced in all constructs to avoid plasmid
instability and difficulty in sequencing.
siRNA expression vectors
piGENE hU6 [14] has the human U6 promoter and a Bsp
MI cloning site. piGENE tRNA Pur [27] has the human
tRNAVal promoter and a multiple cloning site, Sac I/Bgl II/
Not I/Kpn I/Eco RV. Both were obtained from iGENE Ther-
apeutics, Inc. (Tsukuba, Japan). Two vectors modified at
the cloning site were made from piGENE hU6. One had a
Sac I/Kpn I cloning site and the other a naturally occurring
CACC sequence just before the Sac  I/Kpn  cloning site
(Table 3).
Cell culture and transfection
HeLaS3 cells were cultured in Dulbecco's modified Eagle's
medium (Sigma, St. Louis, MO) supplemented with 10%
fetal calf serum. Cells (0.75 × 105/well) were plated in a
24-well plate and, a day after plating, transfected with
plasmid DNA. A typical treatment consisted of 200 μg of
target vector DNA and 200 μg of siRNA expression vector
DNA. Transfection was performed using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manu-
facturer's instructions.
RNAi assays
Cells transfected with fluorescent-protein-expressing plas-
mid DNA were examined under a fluorescence micro-
scope (Olympus IX71, Tokyo). To determine the intensity
of fluorescence quantitatively, cells were lysed with 100
μL of lysis buffer (Promega, Madison, WI) and aliquots
(80  μL) were analyzed using Fluoroskan Ascent FL
(Thermo Labosystems, Helsinki, Finland). To determine
the amount of protein, aliquots (5 μL) were mixed with
200 μL of 5-fold diluted reagent of the Bio-Rad Protein
Assay (Bio-Rad Laboratories-Inc, Hercules, CA), and the
absorption was measured using Multiskan Ascent
(Thermo Labosystems). Comparisons were made on the
basis of fluorescence per μg protein. To measure lumines-
cence, a Dual-luciferase Reporter Assay System (Promega)
was used. The detector was a Sirius Luminometer
(Berthold Detection Systems, Pforzheim, Germany). In
this case, the intensity of the target (Fluc) was divided by
that of the internal control (Rluc) or vice versa and the
ratios were used for comparison.
Immunostaining of PrPC and truncated PrPC
HeLaS3 cells (4 × 104/well, 24-well plate) were plated
and, after 24 h of culturing, pbPrP- FLAG DNA or pshort-
bPrP- FLAG DNA (200 ng) and siRNA expression vector
DNA or control vector DNA (200 ng) were co-transfected
for 4 h. After 24 h, cells were fixed with acetone-methanol
(1:1) and washed with TBS (Tris buffered saline) for 10
min 3 times. After being treated with TBST (TBS with
0.05% Triton X) for 10 min and then washed with TBS
once, cells were blocked with 10% BSA/TBS for 1 h with
shaking. After a brief wash with TBS, cells were stained
with a primary antibody for 1 h. The antibody was anti-
PrPC or anti-FLAG antibody diluted 2000 to 5000 fold.
After another brief wash with TBS, cells were blocked with
3% BSA/TBS for 1 h, and then stained with a secondary
antibody (rabbit anti-mouse-IgG-FITC (SIGMA) diluted
10000 fold) for 1 h. After three washes with TBST, cells
covered with TBS were examined under a fluorescence
microscope (Olympus IX71, Tokyo). One anti-PrPC anti-
body was SIGMA P6488 (SIGMA; host, mouse; isotype,
IgG1), which had been raised against a synthetic peptide
corresponding to amino acid residues 146–159 of bovine
PrPC. Bovine PrPC was identified as a protein of 33–35
kDa that was immunoreactive with P6488, which also can
detect human, sheep, deer, and elk PrPC. Another anti-
PrPC antibody was SAF32 (SPI Bio; host, mouse; isotype,
IgG2b), which recognizes the octo-repeat region located in
the N-terminal part of PrP and cross-reacts with bovine,
human, hamster, mouse, and ovine PrPC. Bovine PrPC and
the truncated PrPC were also detected using the anti-FLAG
antibody M2 (isotype, IgG1) which was one of the compo-
nents of SIGMA's kit (Carboxy-terminal FLAG mamma-
lian transient expression kit).
Western blot analysis
HeLaS3 cells (7 × 105) were plated in a plastic dish 60 mm
in diameter. After 24 h, cells were co-transfected with
pbPrP- FLAG DNA or pshort-bPrP- FLAG (4 μg) for 4 h.
Cells were washed and cultured in fresh medium. After 24
h, they were washed with PBS once and collected in 100
μL of TBS with a rubber policeman. The cells were lysed by
sonication for 3 min on ice. An equal volume of Laemmli
sample buffer (Bio-Rad) containing 5% mercaptoethanol
was added to the cell lysate, and the mixture was boiledBMC Biotechnology 2007, 7:44 http://www.biomedcentral.com/1472-6750/7/44
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for 5 min. Samples were subjected to SDS-PAGE using the
following conditions: electrophoresis buffer, 1 × Tris-gly-
cine-SDS (10 fold dilution of 10 × buffer, Bio-Rad) con-
taining 5% methanol; gel, SuperSep™ 10–20% (Wako
Pure Chemical Industries, Inc., Osaka); markers, ECL
DualVeu Western blotting markers (GE Health Care, Pis-
cataway, NJ); and electrophoresis conditions, 20 mA for
80 min. Proteins were transferred to a Fluorotrans® sheet
(Nippon Genetics, Tokyo) in a Mini Transblot Cell (Bio-
Rad) at 100 V for 60 min. The membrane was blocked
with 5% skim milk/TBST for 1 h at room temperature.
After being washed with TBST for 10 min 3 times, the
membrane was stained with the antibody SAF32 (diluted
1/5000 with TBST) for 1 h with shaking. After 3 washes
with TBST for 10 min each time, the membrane was
stained with a secondary antibody, Anti-mouse IgG-HRP
conjugate (idiluted 1/10000 with TBST, ECL Plus Western
blotting detection kit, GE Healthcare), for 1 h with shak-
ing. After 3 more washes with TBST for 10 min each time,
the membrane was treated with a 40:1 mix of ELC Plus
A:B(iWestern blotting detection kit) for 5 min. Photos
were taken using a LAS-1000 (Fuji) with 30 sec to 2 min
of exposure.
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